President John Kennedy famously said that a rising tide lifts all boats, and that is looking to be the case in today’s ...

Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment ...

In the U.S., Niktimvo will be co-commercialized by Syndax and Incyte. The Company announced Niktimvo was added to the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

BofA Securities has recently raised Incyte Corp (INCY) stock to Buy rating, as announced on October 29, 2024, according to Finviz. Earlier, on October 1, 2024, Wolfe Research had initiated the stock ...

Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...

Another notable valuation metric for BMRN is its P/B ratio of 2.34. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities.

This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...